Vaxcyte Valuation in Focus: Funding and Late-Stage Trials

Vaxcyte has completed a major public equity offering, adding fresh capital to its balance sheet. The company is advancing its 31 valent pneumococcal conjugate vaccine candidate, VAX-31, into multiple Phase 3 trials in adults and infants. The funding event and clinical progress come at the same time and are material for Vaxcyte's development plans in pneumococcal disease.